



June 22, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Intimation of Acquisition of 10,00,000 equity shares of M/s Curexis Ventures Private Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue.

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, Zota Health Care Limited (the “Company”), would like to inform you that the Company has acquired 10,00,000 equity shares of M/s Curexis Ventures Private Limited (“Curexis”), Wholly Owned Subsidiary of the Company, by way of subscription to the right issue.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are annexed herewith as **Annexure-I**.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Group Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601

Email: info@zotahealthcare.com

Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Annexure-I

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc.	i. Name of the Target Entity: Curexis Ventures Private Limited ('Curexis') ii. Business of the Target Entity: established as a drug manufacturing, development, and marketing company. CUREXIS is engaged in the business of running retail pharmacy stores under the brand name of "SKIA" offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products. iii. Financial details: as per the audited financial statements for the Financial Year 2025-26, the turnover of Curexis was Rs. 1.18 Lakhs and the total paid up share capital was Rs. 1 Lakh.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No, the acquisition does not fall within the ambit of related party transactions. The promoter/ promoter group/ group companies do not have any interest in Curexis and the said transaction is done at arm's length basis.
Industry to which the entity being acquired belongs	Pharmaceutical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has made investment in Curexis as a part of strategic investment, expansion of SKIA stores and to mitigate the working capital requirements of Curexis. Post to this acquisition, Curexis continues to remain as the Wholly Owned Subsidiary of the Company.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	On June 22, 2026, the Company has acquired the said 10,00,000 equity shares of Curexis by subscription to the right issue.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration by way of acquisition of Equity Shares.
Cost of acquisition or the price at which the shares are acquired	Cost of acquisition for subscription of 10,00,000 Equity Shares offered on right basis is Rs. 20.00/- per equity share (including premium of Rs. 10.00/- per equity share) aggregating to Rs. 2,00,00,000.00/-.
Percentage of shareholding / control acquired and / or number of shares acquired	The Company has acquired 10,00,000 equity shares of Curexis. Post to this acquisition, Curexis continues to remain as the Wholly-owned Subsidiary of the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Curexis was incorporated on February 25, 2025, domiciled in India; engaged in drug manufacturing, development, and marketing company. CUREXIS is engaged in the business of running retail pharmacy stores under the brand name of "SKIA" offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products. During last three financial years, the details of turnover of Curexis were as follows: FY 2025-26 Rs. 1.18 Lakhs FY 2024-25 Rs. NIL FY 2023-24: N.A.